profit from every $100 of sales.
$0$100
AbCellera Biologics
$11.95-4.09% today
+198.0% in 1 year
1-year low $2.781-year high $14.82
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What AbCellera Biologics sold, what it kept, and what it did with the cash.
Sales went from $485 million in 2022 to $75.1 million in 2025, with -$146 million of profit last year.
SalesProfit
AbCellera Biologics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| AbCellera Biologics | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads AbCellera Biologics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 485 | 38 | 29 | 75 | |
| 419 | 38 | 29 | – | |
| 227 | -223 | -301 | -203 | |
| 260 | -192 | -204 | -174 | |
| 159 | -146 | -163 | -146 | |
| 0.50 | -0.51 | -0.55 | -0.49 | |
| 86.3% | 100.0% | 100.0% | – | |
| 46.8% | -586.6% | -1,044.4% | -270.5% | |
| 32.7% | -385.0% | -564.8% | -194.9% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 1,541 | 1,488 | 1,361 | 1,357 |
| Cash | 387 | 133 | 156 | 129 |
| Total debt | 82 | 77 | 65 | 143 |
| Total liabilities | 308 | 336 | 304 | 390 |
| 1,233 | 1,152 | 1,056 | 967 | |
| 315 | 289 | 294 | 299 | |
| 13.6% | -14.3% | -21.2% | -14.5% | |
| 12.9% | -12.7% | -15.4% | -15.1% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 277 | -44 | -109 | -131 | |
| 73 | 77 | 78 | 43 | |
| 205 | -121 | -187 | -174 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 49 | 64 | 68 | 56 |
Valuation
- –
- –
- –
- 3.7×
- 52.0×
- –
- –
- -4.5%
- -3.8%
- 0.0%
Profitability
- 79.1%
- -270.5%
- -194.9%
- -220.5%
- -14.8%
- -9.3%
- -14.2%
- -11.0%
- -16.8%
- 241.1%
Growth
- −46.3%
- –
- +6.9%
- –
- −1.7%
Financial health
- –
- 0.15
- 10.7%
- –
- 11.32
- 14.05
- 0.06
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 21%of 958
Bottom 1%of 889
Bottom 19%of 987
What analysts expect
- Average price target
- $7.00
- Range
- $7.00 – $7.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 11, 2026 | -0.14 | -0.22 | +36.4% |
| Feb 24, 2026 | -0.03 | -0.18 | +83.3% |
| Nov 6, 2025 | -0.19 | -0.17 | −11.8% |
| Aug 7, 2025 | -0.12 | -0.17 | +29.4% |
| May 8, 2025 | -0.15 | -0.17 | +11.8% |
| Feb 27, 2025 | -0.11 | -0.15 | +26.7% |
| Nov 4, 2024 | -0.17 | -0.14 | −21.4% |
| Aug 6, 2024 | -0.13 | -0.15 | +13.3% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
38No pass
Benjamin Graham
41No pass
Philip Fisher
52No pass
Peter Lynch
29No pass
Joel Greenblatt
2No pass
Charlie Munger
49No pass
Terry Smith
48No pass
Questions about AbCellera Biologics
Is AbCellera Biologics a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the AbCellera Biologics AI analysis
What does AbCellera Biologics do?
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. It is in Biotechnology.
Does AbCellera Biologics pay a dividend?
No. AbCellera Biologics does not pay a dividend at the moment.
Is AbCellera Biologics stock halal?
Yes. AbCellera Biologics passes our halal screen: its business is permitted and its debt is 4% of its market value, under the 30% limit. How we check
How has AbCellera Biologics stock done over the past year?
Up 198.0% over the past twelve months, to $11.95. It traded between $2.78 and $14.82 and is 19.4% below its high.
Who are AbCellera Biologics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with AbCellera Biologics's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.